GlassScriptPhysician profile
Cartrina Danner
NPI 1811606585
$1,990.01
in general payments reported to CMS, 2019-2025
20 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.89 · 2023: $1,189 · 2024: $561 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.26 | 2023-2025 | |
| Corium, LLC | $188.23 | 2023-2024 | Azstarys |
| Alkermes, INC. | $179.41 | 2023 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.07 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $99.92 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $93.60 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $92.54 | 2023-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $87.65 | 2023-2024 | Austedo Xr, Austedo |
| Lundbeck LLC | $83.27 | 2023-2024 | Rexulti |
| Bausch Health US, LLC | $41.09 | 2023 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $35.66 | 2024-2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.76 | 2023 | Rexulti |
| Neos Therapeutics, LP | $20.36 | 2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $18.47 | 2023 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $18.43 | 2024 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $17.58 | 2024 | Neurostar Tms Therapy System |
| Indivior INC. | $15.31 | 2023 | Perseris |
| Noven Therapeutics, LLC | $14.13 | 2023 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $13.28 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cartrina Danner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.